Skip to main content

Parkinson's Disease clinical trials at UC Health
38 in progress, 15 open to eligible people

  • A Study of LY3154207 in Participants With Parkinson's Disease Dementia

    open to eligible people ages 40-85

    A randomized placebo-controlled trial to evaluate the safety and efficacy of three doses of study drug LY3154207 treated for 12 weeks in participants with mild-to-moderate dementia associated with LBD (PDD or DLB).

    at UC Davis UC Irvine

  • A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Patients With Motor Fluctuations

    open to eligible people ages 40 years and up

    To evaluate the safety and efficacy of IPX203 (carbidopa and levodopa) extended-release capsules (IPX203 ER CD-LD) in comparison to immediate release (IR) CD-LD in the treatment of CD-LD-experienced subjects with Parkinson's disease (PD) who have motor fluctuations.

    at UC Irvine

  • Antigen Presentation and Lymphocyte Response in Parkinson's Disease

    open to eligible people ages 50-90

    The way the immune system responds to certain PD-related proteins in PD donors compared to the way it responds in persons without or fewer PD related proteins is not well studied and this study aims to analyze the autoimmune response in each group. The study involves a one time visit involving brief questionnaires and a blood draw of 30 mL (approximately 2 tablespoons) to be collected.

    at UCSD

  • Clinical research study of a gene therapy for patients with Parkinson's Disease (RESTORE-1)

    “Please consider this clinical research study evaluating the safety and efficacy of an investigational gene therapy in Parkinson's Disease”

    open to eligible people ages 40-75

    The objectives of this study are to assess the distribution, efficacy, and safety of VY-AADC02 in Patients with Parkinson's Disease with Motor Fluctuations.

    at UC Davis UC Irvine UCSF

  • Invasive Approach to Model Human Cortex-Basal Ganglia Action-Regulating Networks

    open to eligible people ages 18 years and up

    The brain networks controlling movement are complex, involving multiple areas of the brain. Some neurological diseases, like Parkinson's disease, cause abnormalities in the brain networks. Deep brain stimulation is a treatment that is used to treat these types of neurological diseases. Through this research, the investigators will take advantage of the unique opportunity provided by awake deep brain stimulation surgery to learn more about how the brain functions in a diseased state and how deep brain stimulation changes these networks. This study aims to enroll up to 75 subjects over a period of 2.5 years. Those who participate in the study will spend up to 40 minutes during their deep brain stimulation surgery during which researchers will record signals from deep structures within the brain as well as the surface of the brain using electrodes that are temporarily placed for research purposes. During the study, researchers will record signals while subjects perform three different tasks, in some cases while the brain is stimulated. Study participation is limited to the intraoperative environment with no additional study visits required.

    at UCLA UCSD UCSF

  • Low Frequency Deep Brain Stimulation of cognitive performance in Parkinson's Disease

    “Research evaluating memory and thinking ability”

    open to eligible people ages 18 years and up

    Prospective trial of low frequency deep brain stimulation of the ventral subthalamic nucleus to improve cognitive performance in patients with advanced Parkinson's disease. All study participants have undergone DBS implantation surgery as part of their routine care for motor manifestations of Parkinson's disease. In this study, a temporary low frequency period of stimulation will be applied to determine its effects on cognition.

    at UC Davis

  • Microbiota Intervention to Change the Response of Parkinson's Disease

    open to eligible people ages 30 years and up

    The clinical phenotype of Parkinson's disease (PD) is quite variable, as is the response to and side effects from medications. While many patients respond to carbidopa/levodopa early on, motor fluctuations and dyskinesias can become a problem as the condition progresses, causing significant impairment in function and quality of life. The gut microbiome is of increasing interest in PD, potentially contributing to pathophysiology and clinical phenotype. Furthermore, gut bacteria are capable of metabolizing levodopa, which may decrease its ability to reach the central nervous system and could explain the variable effect seen clinically. Altering the population of drug-metabolizing bacteria could improve the clinical symptoms of PD and the benefit seen with medications. The investigators hypothesize that the gut microbiome in people with PD correlates with their phenotypic characteristics, which can be improved with targeting the microbiome through dietary or therapeutic interventions. The investigators propose a two-part clinical trial. First, a cross-sectional analysis will correlate the microbiome profile with (a) the clinical phenotype of PD and (b) medication response. Second, a randomized, controlled trial, will evaluate the effect of microbiome manipulation on clinical phenotype and medication response. The investigators plan to reduce the level of bacteria through antibiotic use, resetting the potentially disadvantageous microbiome population. Outcomes will include changes in clinical symptoms, alterations in the the microbiome, and changes in serum markers of inflammation. This thorough characterization will broaden our understanding of the gut-brain axis significantly in PD in clinically relevant ways that have yet to be explored.

    at UCSF

  • Mindfulness-based Cognitive Therapy (MBCT) for People With Parkinson's Disease

    open to eligible people ages 18 years and up

    This study aims to explore the feasibility and effectiveness of mindfulness-based cognitive therapy (MBCT) in reducing anxiety and/or depressive symptoms in people with Parkinson's disease.

    at UCSF

  • More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease

    open to eligible people ages 18-105

    This is a two-center (University of Colorado, University of California San Francisco) community-based comparative effectiveness study of outpatient palliative care for Parkinson's disease (PD) and related disorders (progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), multiple systems atrophy (MSA), Lewy Body Dementia (LBD). In September 2018, the study was amended to also include Alzheimer's disease (AD) and related disorders (Frontotemporal Dementia (FTD), Primary Progressive Aphasia (PPA), Vascular Dementia). It will utilize a randomized stepped-wedge design to compare patient and caregiver outcomes between usual care in the community versus usual care augmented by palliative training and telemedicine support to provide other resources (e.g. social work).

    at UCSF

  • North American Prodromal Synucleinopathy Consortium

    open to eligible people ages 18 years and up

    This study will enroll participants with idiopathic rapid eye movement (REM) sleep behavior disorder (RBD), for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.

    at UCLA

  • PDGeneration: Mapping the Future of Parkinson's Disease

    open to eligible people ages 18 years and up

    To assess the feasibility, impact, and participant satisfaction of offering Clinical Laboratory Improvement Amendments (CLIA) certified genetic testing as part of clinical care for People with Parkinson's disease (PWP).

    at UCSD

  • SMARTfit Training for Parkinson's Disease

    open to eligible people ages 50-85

    This pilot study aims to investigate the effects of 8-week SMARTfit training versus conventional physical training on motor function, cognition and brain functional connectivity in individuals with PD. The investigators hypothesize that clinical and physical performance will improve after SMARTfit training more than after conventional physical training.

    at UC Irvine

  • Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression

    open to eligible people ages 30 years and up

    This is a observational, multi-center study to assess progression of clinical features, imaging and biologic biomarkers in Parkinson disease (PD) patients compared to healthy controls (HC) and in PD patient subtypes. The primary objective of this study is to identify clinical, imaging and biologic markers of PD progression for use in clinical trials of disease-modifying therapies.

    at UCSD UCSF

  • The Motor Network in Parkinson's Disease and Dystonia: Mechanisms of Therapy

    open to eligible people ages 21-75

    This is an exploratory pilot study to identify neural correlates of specific motor signs in Parkinson's disease (PD) and dystonia, using a novel totally implanted neural interface that senses brain activity as well as delivering therapeutic stimulation. Parkinson's disease and isolated dystonia patients will be implanted unilaterally or bilaterally with a totally internalized bidirectional neural interface, Medtronic Summit RC+S. This study includes three populations: ten PD patients undergoing deep brain stimulation in the subthalamic nucleus (STN), ten PD patients with a globus pallidus (GPi) target and five dystonia patients. All groups will test a variety of strategies for feedback-controlled deep brain stimulation. Only the STN patients will undergo a blinded, small pilot clinical trial of closed-loop stimulation for thirty days.

    at UCSF

  • The Parkinson's Genetic Research Study

    open to eligible people ages 18 years and up

    The Parkinson's Genetic Research Study (PaGeR), headed by Dr. Cyrus Zabetian, is searching for genes that increase the risk of developing Parkinson's disease (PD) and related disorders. The study is a joint effort by neurologists and researchers across the United States and is sponsored by the National Institutes of Health. The coordinating center for PaGeR is located at the University of Washington and the VA Puget Sound Health Care System in Seattle.

    at UCSD

  • A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients

    Sorry, in progress, not accepting new patients

    The purpose of this study is to determine whether the gastric retentive Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD) is more effective than the commercially available immediate release Carbidopa/Levodopa in reducing motor fluctuations such as "off time" in advanced Parkinson's Disease patients.

    at UC Davis

  • A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease

    Sorry, in progress, not accepting new patients

    This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhibitors since baseline. The study will consist of 2 parts: a 52-week, double-blind, placebo-controlled treatment period (Part 1) after which eligible participants will continue into an all-participants-on-treatment blinded dose extension for an additional 52 weeks (Part 2).

    at UCSF

  • An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

    Sorry, not currently recruiting here

    An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

    at UC Irvine

  • Chronic Effects of DBS in Parkinson's Disease and Dystonia

    Sorry, in progress, not accepting new patients

    The purpose of this study is to use an investigational device to record brain activity for 12-24 months following surgical implantation of deep brain stimulation (DBS) systems. The goal of the study is better understanding of brain activity in movement disorders and how they relate to DBS, not to bring new devices to market.

    at UCSF

  • Cognitive Rehabilitation for PD-MCI

    Sorry, in progress, not accepting new patients

    To investigate the effectiveness of a novel compensatory cognitive rehabilitation program for individuals with Parkinson's disease (PD) and mild cognitive impairment (MCI).

    at UCSD

  • Cortical Stimulation to Treat Mood and Behavioral Symptoms in Parkinson's Disease Patients

    Sorry, in progress, not accepting new patients

    This study will investigate cortical stimulation to treat mood and behavioral symptoms in Parkinson's disease patients.

    at UCSF

  • Deep Brain Stimulation (DBS) for the Treatment of Parkinson's Disease

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the safety and effectiveness of Boston Scientific's Vercise Deep Brain Stimulation (DBS) system in the treatment of patients with with advanced, levodopa-responsive bilateral Parkinson's disease (PD) which is not adequately controlled with medication.

    at UCSF

  • Does Outpatient Palliative Care Improve Patient-centered Outcomes in Parkinson's Disease?

    Sorry, in progress, not accepting new patients

    The purpose of this study is to improve outcomes for persons living with Parkinson's Disease (PD) and their family caregivers. The investigators hypothesize that outpatient interdisciplinary palliative care will improve patient-centered outcomes for PD patients at high-risk for poor outcomes.

    at UCSF

  • Effects of Osteopathic Manipulative Treatment (OMT) on Gait Biomechanics in Parkinson's Disease

    Sorry, in progress, not accepting new patients

    Parkinson's disease (PD) is a neurological disorder that puts individuals at high risk for injuries and long-term disabilities as a result of a fall or other trauma. Injuries sustained from falls account for many deaths as well as thousands of hospital admissions and nursing home stays every month. Quality of life and even longevity itself is reduced due to the resulting surgeries, immobility, complications and even cognitive impairments that can follow. The proposed study will explore beneficial impact of a treatment modality (OMM/OMT) that may significantly reduce the morbidity of this condition by comparing 6 weeks of OMT versus 6 weeks light touch intervention versus 6 weeks care as usual to improve gait in individuals with PD. Gait will be measured at mid-treatment, post-treatment and 4-week follow-up.

    at UCSD

  • Efficacy of Isradipine in Early Parkinson Disease

    Sorry, in progress, not accepting new patients

    The purpose of the study is to determine whether treatment with isradipine is effective in slowing the progression of Parkinson disease disability.

    at UC Irvine UCSD UCSF

  • Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease

    Sorry, in progress, not accepting new patients

    To evaluate the dose-related safety of BIIB054, to evaluate the pharmacodynamic effects of BIIB054 on the integrity of nigrostriatal dopaminergic nerve terminals, to assess the pharmacokinetic (PK) profile of BIIB054 and to evaluate the immunogenicity of BIIB054.

    at UCSF

  • Exercise Targeting Cognitive Impairment in Parkinson's Disease

    Sorry, in progress, not accepting new patients

    The aim of this application is to compare and elucidate the effects of skill-based versus aerobic exercise versus control on mild cognitive impairment (MCI) of the executive function (EF) subtype in Parkinson's disease (PD); we hypothesize that skill-based exercise will result in the greatest improvement in EF and lead to modification of underlying neural substrates.

    at UCLA

  • Experimental drug Nilotinib in Parkinson's Disease

    Sorry, in progress, not accepting new patients

    This study will assess the safety and tolerability of daily oral administration of nilotinib (150-300mg once daily) in Parkinson's Disease.

    at UC Davis

  • Infusion of Apomorphine: Long-term Safety Study

    Sorry, in progress, not accepting new patients

    This is a Phase 3, multicenter, open-label, safety and tolerability study of continuous apomorphine infusion in subjects with advanced Parkinson's Disease (PD) whose motor fluctuations remain unsatisfactory with levodopa (or levodopa/carbidopa) and at least one other class of drugs or mode of therapy for PD.

    at UCLA

  • Mindfulness Based Stress Reduction for Parkinson's Disease: A Longitudinal Study

    Sorry, not yet accepting patients

    To investigate the efficacy of Mindfulness-based Stress Reduction (MBSR),to improve HRQoL, cognition, and mood, as well as to determine the longevity of the treatment response in individuals with Parkinson's disease (PD).

    at UCSD

  • Observational, Long-term, Extension Study for Participants of Prior VY-AADC01 or VY-AADC02 Studies

    Sorry, accepting new patients by invitation only

    An extension study for participants who have completed VY-AADC01 or VY-AADC02 Studies

    at UCSF

  • Safety and Biomarker Study of EPI-589 in Parkinson's Disease

    Sorry, in progress, not accepting new patients

    Open-label study with 30-day run-in phase and adaptive design component to include more subjects if deemed appropriate by investigators.

    at UCSF

  • Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease

    Sorry, in progress, not accepting new patients

    Safety and efficacy of AADC gene transfer in participants with Parkinson's disease.

    at UCSF

  • Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease

    Sorry, in progress, not accepting new patients

    Safety study of AADC gene transfer (VY-AADC01) in subjects with Parkinson's disease.

    at UCSF

  • Study of Urate Elevation in Parkinson's Disease, Phase 3

    Sorry, in progress, not accepting new patients

    A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial to determine whether oral inosine dosed to moderately elevate serum urate (from ≤5.7 mg/dL to 7.1-8.0 mg/dL) over 2 years slows clinical decline in early PD. Clinical decline will be assessed as change in the primary outcome variable of the Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), a composite scale comprising patient- and clinician-reported outcomes.

    at UC Davis UCSD UCSF

  • Trial of Parkinson's And Zoledronic Acid

    Sorry, not yet accepting patients

    This study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 65 years and older with Parkinson's Disease with 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.

    at UCSF

  • Use of Interventional MRI for Implantation of Deep Brain Stimulator Electrodes

    Sorry, accepting new patients by invitation only

    The purpose of this study is to gather observational data on an already FDA-approved implantation technique for deep brain stimulation (DBS) in which the entire surgery is performed within an MRI scanner ("interventional MRI", or iMRI). With this surgical technique, the patient is fully asleep (under general anesthesia) during DBS implantation. The standard method for the placement of deep brain stimulators does not use MRI during the actual DBS placement. The standard method involves placement of a rigid frame on the patient's head, performance of a short MRI scan, transport to the operating room, placement of the DBS electrodes in the operating room, and return to the MRI suite for another MR to confirm correct electrode placement. In the standard method, the patient must be awake for 2-4 hours in the operating room to have "brain mapping" performed, where the brain target is confirmed by passing "microelectrodes" (thin wires) into the brain to record its electrical activity. In the standard method, general anesthesia is not required. With the iMRI technique, the surgery is guided entirely by MRI images performed multiple times as the DBS electrode is advanced. This eliminates the need for the patient to be awake, and eliminates the need for passing microelectrodes into the brain before placing the permanent DBS electrode.

    at UCSF

  • Wearable Assessments in the Clinic and Home in PD

    Sorry, not currently recruiting here

    The purpose of this study is to evaluate disease progression in persons with early Parkinson disease, as assessed by digital and electronic sensor data collection to be correlated with typical clinical assessments.

    at UC Davis UCSF

Last updated: